Singapore markets open in 1 hour 28 minutes
Straits Times Index
3,272.72 +47.55 (+1.47%) S&P 500
5,070.55 +59.95 (+1.20%) Dow
38,503.69 +263.71 (+0.69%) Nasdaq
15,696.64 +245.33 (+1.59%) Bitcoin USD
66,352.66 -712.16 (-1.06%) CMC Crypto 200
1,426.69 +11.93 (+0.84%)
Incyte Corporation (INCY)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 51.92 |
| Open | 52.00 |
| Bid | 51.60 x 300 |
| Ask | 51.65 x 300 |
| Day's range | 51.39 - 52.22 |
| 52-week range | 50.27 - 75.74 |
| Volume | |
| Avg. volume | 1,730,346 |
| Market cap | 11.597B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | 19.49 |
| EPS (TTM) | 2.65 |
| Earnings date | 30 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 74.88 |
ZacksIncyte (INCY) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksIncyte (INCY) to Report Q1 Earnings: What's in the Cards?
Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
Business WireIncyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
WILMINGTON, Del. & SAN DIEGO, April 23, 2024--Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
© 2024 Yahoo. All rights reserved.